MACROH2A1 and myelodysplastic syndrome: To assess the levels of mH2A1 within the tumor microenvironment, we analyzed its expression in BM biopsies from healthy controls (n = 4) and MDS patients (22 of 41 enrolled in the study) by immunohistochemistry.